PPMD is pleased to announce that late yesterday we submitted the results of our most recent patient-centered benefit-risk assessment (PCBR) study to the FDA. The assessment was done with research partners at the Johns Hopkins Bloomberg School of Public Health. PCBR assessment is an increasingly-favored…
ContinueAdded by PPMD on October 22, 2015 at 7:48am — No Comments
PPMD is proud to help author and share the attached letter to Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research at the FDA. Along with CDMD at…
ContinueAdded by PPMD on October 19, 2015 at 11:00am — No Comments
Today we learned that the FDA will host an Advisory Committee (Ad Comm) meeting on November 24 to discuss the NDA for BioMarin’s drisapersen…
ContinueAdded by Pat Furlong on October 14, 2015 at 4:30pm — No Comments
Yesterday, I had the distinct privilege of representing PPMD and our Duchenne community as I sat before a full room of Senate staffers and congressional aides in the Dirksen Senate office building. Our goal was to urge them to press forward on the Innovation for Healthier Americans bill (also referred to as the ‘Innovation…
ContinueAdded by Annie Kennedy on October 9, 2015 at 12:00pm — 1 Comment
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service